|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dueñas-Gonzalez A, Cetina L, Mariscal I
and de la Garza J: Modern management of locally advanced cervical
carcinoma. Cancer Treat Rev. 29:389–399. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Glick SB, Clarke AR, Blanchard A and
Whitaker AK: Cervical cancer screening, diagnosis and treatment
interventions for racial and ethnic minorities: A systematic
review. J Gen Intern Med. 27:1016–1032. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sakuragi N: Up-to-date management of lymph
node metastasis and the role of tailored lymphadenectomy in
cervical cancer. Int J Clin Oncol. 12:165–175. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Su Y, Xiong J, Hu J, Wei X, Zhang X and
Rao L: MicroRNA-140-5p targets insulin like growth factor 2 mRNA
binding protein 1 (IGF2BP1) to suppress cervical cancer growth and
metastasis. Oncotarget. 7:68397–68411. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yi Y, Li H, Lv Q, Wu K and Zhang W, Zhang
J, Zhu D, Liu Q and Zhang W: miR-202 inhibits the progression of
human cervical cancer through inhibition of cyclin D1. Oncotarget.
7:72067–72075. 2016.PubMed/NCBI
|
|
10
|
Miller TE, Ghoshal K, Ramaswamy B, Roy S,
Datta J, Shapiro CL, Jacob S and Majumder S: MicroRNA-221/222
confers tamoxifen resistance in breast cancer by targeting
p27Kip1. J Biol Chem. 283:29897–29903. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tsang WP, Ng EK, Ng SS, Jin H, Yu J, Sung
JJ and Kwok TT: Oncofetal H19-derived miR-675 regulates tumor
suppressor RB in human colorectal cancer. Carcinogenesis.
31:350–358. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jin Y, Peng D, Shen Y, Xu M, Liang Y, Xiao
B and Lu J: MicroRNA-376c inhibits cell proliferation and invasion
in osteosarcoma by targeting to transforming growth factor-alpha.
DNA Cell Biol. 32:302–309. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang Z, Liu M, Zhu H, Zhang W, He S, Hu C,
Quan L, Bai J and Xu N: miR-106a is frequently upregulated in
gastric cancer and inhibits the extrinsic apoptotic pathway by
targeting FAS. Mol Carcinog. 52:634–646. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xiao B, Guo J, Miao Y, Jiang Z, Huan R,
Zhang Y, Li D and Zhong J: Detection of miR-106a in gastric
carcinoma and its clinical significance. Clin Chim Acta.
400:97–102. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhu M, Zhang N, He S, Lui Y, Lu G and Zhao
L: MicroRNA-106a targets TIMP2 to regulate invasion and metastasis
of gastric cancer. FEBS Lett. 588:600–607. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li P, Xu Q, Zhang D, Li X, Han L, Lei J,
Duan W, Ma Q, Wu Z and Wang Z: Upregulated miR-106a plays an
oncogenic role in pancreatic cancer. FEBS Lett. 588:705–712. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang R, Li Y, Hou Y, Yang Q, Chen S, Wang
X, Wang Z, Yang Y, Chen C, Wang Z, et al: The
PDGF-D/miR-106a/Twist1 pathway orchestrates epithelial-mesenchymal
transition in gemcitabine resistance hepatoma cells. Oncotarget.
6:7000–7010. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen L, Zhang F, Sheng XG, Zhang SQ, Chen
YT and Liu BW: MicroRNA-106a regulates phosphatase and tensin
homologue expression and promotes the proliferation and invasion of
ovarian cancer cells. Oncol Rep. 36:2135–2141. 2016.PubMed/NCBI
|
|
19
|
Zhu M, Zhang N, He S, Yan R and Zhang J:
MicroRNA-106a functions as an oncogene in human gastric cancer and
contributes to proliferation and metastasis in vitro and in vivo.
Clin Exp Metastasis. 33:509–519. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hou X, Zhang M and Qiao H: Diagnostic
significance of miR-106a in gastric cancer. Int J Clin Exp Pathol.
8:13096–13101. 2015.PubMed/NCBI
|
|
21
|
Yuan R, Zhi Q, Zhao H, Han Y, Gao L, Wang
B, Kou Z, Guo Z, He S, Xue X, et al: Upregulated expression of
miR-106a by DNA hypomethylation plays an oncogenic role in
hepatocellular carcinoma. Tumour Biol. 36:3093–3100. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
He QY, Wang GC, Zhang H, Tong DK, Ding C,
Liu K, Ji F, Zhu X and Yang S: miR-106a-5p suppresses the
proliferation, migration, and invasion of osteosarcoma cells by
targeting HMGA2. DNA Cell Biol. 35:506–520. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhi F, Zhou G, Shao N, Xia X, Shi Y, Wang
Q, Zhang Y, Wang R, Xue L, Wang S, et al: miR-106a-5p inhibits the
proliferation and migration of astrocytoma cells and promotes
apoptosis by targeting FASTK. PLoS One. 8:e723902013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ma Y, Zhang H, He X, Song H, Qiang Y, Li
Y, Gao J and Wang Z: miR-106a* inhibits the proliferation of renal
carcinoma cells by targeting IRS-2. Tumour Biol. 36:8389–8398.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yang G, Zhang R, Chen X, Mu Y, Ai J, Shi
C, Liu Y, Shi C, Sun L, Rainov NG, et al: miR-106a inhibits glioma
cell growth by targeting E2F1 independent of p53 status. J Mol Med
(Berl). 89:1037–1050. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Deng Y, Xiong Y and Liu Y: miR-376c
inhibits cervical cancer cell proliferation and invasion by
targeting BMI1. Int J Exp Pathol. 97:257–265. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Deng B, Zhang Y, Zhang S, Wen F, Miao Y
and Guo K: MicroRNA-142-3p inhibits cell proliferation and invasion
of cervical cancer cells by targeting FZD7. Tumour Biol.
36:8065–8073. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liu S, Zhang P, Chen Z, Liu M, Li X and
Tang H: MicroRNA-7 downregulates XIAP expression to suppress cell
growth and promote apoptosis in cervical cancer cells. FEBS Lett.
587:2247–2253. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rothschild SI, Gautschi O, Batliner J,
Gugger M, Fey MF and Tschan MP: MicroRNA-106a targets autophagy and
enhances sensitivity of lung cancer cells to Src inhibitors. Lung
Cancer. 107:73–83. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Servín-González LS, Granados-López AJ and
López JA: Families of microRNAs expressed in clusters regulate cell
signaling in cervical cancer. Int J Mol Sci. 16:12773–12790. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Nagase H and Woessner JF Jr: Matrix
metalloproteinases. J Biol Chem. 274:21491–21494. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cardeal LB, Boccardo E, Termini L,
Rabachini T, Andreoli MA, di Loreto C, Filho A Longatto, Villa LL
and Maria-Engler SS: HPV16 oncoproteins induce MMPs/RECK-TIMP-2
imbalance in primary keratinocytes: Possible implications in
cervical carcinogenesis. PLoS One. 7:e335852012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Braicu EI, Fotopoulou C, Chekerov R,
Richter R, Blohmer J, Kümmel S, Stamatian F, Yalcinkaya I, Mentze
M, Lichtenegger W, et al: Role of serum concentration of VEGFR1 and
TIMP2 on clinical outcome in primary cervical cancer: Results of a
companion protocol of the randomized, NOGGO-AGO phase III adjuvant
trial of simultaneous cisplatin-based radiochemotherapy vs.
carboplatin and paclitaxel containing sequential radiotherapy.
Cytokine. 61:755–758. 2013. View Article : Google Scholar : PubMed/NCBI
|
